Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 9/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876275 | 0.92 | PDE1A (0.36) | MAT2ALRRK2PDE4B | |
| SCHEMBL25876077 | 0.90 | MERTK (0.35) | MAT2ALRRK2PDE4B | |
| SCHEMBL25876233 | 0.90 | MAT2A (0.33) | MAT2ALRRK2PDE4B | |
| SCHEMBL25876041 | 0.89 | MAT2A (0.35) | MAT2ALRRK2PDE4B | |
| SCHEMBL25875946 | 0.89 | MAT2A (0.40) | MAT2APDE4B | |
| SCHEMBL25875993 | 0.89 | MAT2A (0.33) | MAT2ALRRK2PDE4B | |
| SCHEMBL25876299 | 0.89 | LRRK2 (0.36) | MAT2ALRRK2PDE4B | |
| SCHEMBL25875863 | 0.87 | PDE2A (0.41) | PDE4B | |
| SCHEMBL25876131 | 0.86 | PDE9A (0.34) | — | |
| SCHEMBL25875902 | 0.85 | DGAT1 (0.33) | MAT2APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | MAT2A 686/4885LRRK2 181/4885PDE4B 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.